Who was studied?
One patient with previously treated metastatic triple-negative breast cancer.
What does the publication report?
Target and observed lesions achieved partial responses. This case should not be counted as an independent trial cohort.
Safety findings
A grade 2 skin reaction improved after antiallergic treatment.
How should we interpret it?
A single patient cannot establish efficacy or predict an individual outcome. Prior and concurrent treatments limit attribution.
Read the original source
This independently written summary was checked against the publicly available abstract. It is not a translation of the full paper or a clinical recommendation.
PD-1 inhibitor combined with SBRT, GM-CSF, and thymosin alpha-1 in metastatic breast cancer: A case report and literature review · DOI: 10.1097/MD.0000000000039271 · PMID: 39183403
Educational reporting, not individualized medical advice. Discuss treatment decisions with your clinical team.